December 12, 2024
(press release)
–
Sukhothai, Thailand: The sublingual administration of oil extracts containing plant-derived cannabinoids significantly reduces knee pain in subjects suffering from treatment-resistant osteoarthritis, according to clinical data published in the Journal of Southeast Asian Orthopaedics. A team of Thai investigators conducted a randomized, double-blind, placebo-controlled clinical trial involving 32 patients diagnosed with severe osteoarthritic knee pain. All the participants in the study were awaiting total knee arthroplasty. Participants consumed either oral extracts containing THC (4.59 mg/drop) and CBD (24.25 mg/drop) or a placebo (coconut oil) for 30 days in addition to traditional prescription medications. Patients’ pain scores “demonstrated a statistically significant improvement” following cannabis treatment, researchers reported. The study’s authors concluded: “Cannabis oil significantly reduced pain intensity and improved the QOL [quality of life] in patients with knee OA, as reflected by improvements in the NRS [Numeric Rating Scale]and KOOS [Knee Injury and Osteoarthritis Outcome] scores. … Future research with optimized dosages, larger sample sizes, and longer follow-up periods is needed to evaluate its true clinical relevance.” Full text of the study, “Effectiveness of cannabis oil as an adjuvant therapy in patients with severe knee osteoarthritis: A randomized, double-blind study,” appears in the Journal of Southeast Asian Orthopaedics. Additional information on cannabis and arthritis is available from NORML’s publication, Clinical Applications for Cannabis & Cannabinoids.
* All content is copyrighted by Industry Intelligence, or the original respective author or source. You may not recirculate, redistrubte or publish the analysis and presentation included in the service without Industry Intelligence's prior written consent. Please review our terms of use.
